Seelos Therapeutics Inc.

11/24/2021 | Press release | Distributed by Public on 11/24/2021 07:22

Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine - Form 8-K